Brain metastases (BMs) represent a negative prognostic factor for patients with solid malignancies. BMs are generally approached with loco-regional treatments and the blood-brain barrier limits the efficacy of some systemic drugs. The aim of this review is to summarize current knowledge about the role of immune checkpoint inhibitors for the management of brain metastases in patients with solid malignancies. We performed a review of available literature. Immune checkpoint inhibitors represent the standard treatment for several advanced solid malignancies. However, with the exception of melanoma their clinical role in other solid malignancies is not completely clear due to the exclusion of patients with BM from approval clinical trials. Immune-checkpoint inhibitors may be an effective treatment of brain metastases of melanoma while their clinical role on brain metastases from other solid malignancies is uncertain.

Di Nunno Vincenzo, Nuvola Giacomo, Mosca Mirta, Maggio Ilaria, Gatto Lidia, Tosoni Alicia, et al. (2021). Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases. IMMUNOTHERAPY, 13(5), 419-432 [10.2217/imt-2020-0208].

Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases

Di Nunno Vincenzo;Nuvola Giacomo;Mosca Mirta;Maggio Ilaria;Gatto Lidia;Lodi Raffaele;Franceschi Enrico;
2021

Abstract

Brain metastases (BMs) represent a negative prognostic factor for patients with solid malignancies. BMs are generally approached with loco-regional treatments and the blood-brain barrier limits the efficacy of some systemic drugs. The aim of this review is to summarize current knowledge about the role of immune checkpoint inhibitors for the management of brain metastases in patients with solid malignancies. We performed a review of available literature. Immune checkpoint inhibitors represent the standard treatment for several advanced solid malignancies. However, with the exception of melanoma their clinical role in other solid malignancies is not completely clear due to the exclusion of patients with BM from approval clinical trials. Immune-checkpoint inhibitors may be an effective treatment of brain metastases of melanoma while their clinical role on brain metastases from other solid malignancies is uncertain.
2021
Di Nunno Vincenzo, Nuvola Giacomo, Mosca Mirta, Maggio Ilaria, Gatto Lidia, Tosoni Alicia, et al. (2021). Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases. IMMUNOTHERAPY, 13(5), 419-432 [10.2217/imt-2020-0208].
Di Nunno Vincenzo; Nuvola Giacomo; Mosca Mirta; Maggio Ilaria; Gatto Lidia; Tosoni Alicia; Lodi Raffaele; Franceschi Enrico; Brandes Alba Ariela...espandi
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/868538
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 8
social impact